Search results
Results from the WOW.Com Content Network
Although in classical case–control studies, it remains true that the odds ratio can only approximate the relative risk in the case of rare diseases, there is a number of other types of studies (case–cohort, nested case–control, cohort studies) in which it was later shown that the odds ratio of exposure can be used to estimate the relative ...
Recall bias is of particular concern in retrospective studies that use a case-control design to investigate the etiology of a disease or psychiatric condition. [ 3 ] [ 4 ] [ 5 ] For example, in studies of risk factors for breast cancer , women who have had the disease may search their memories more thoroughly than members of the unaffected ...
For example, recall bias is likely to occur in cross-sectional or case-control studies where subjects are asked to recall exposure to risk factors. Subjects with the relevant condition (e.g. breast cancer) may be more likely to recall the relevant exposures that they had undergone (e.g. hormone replacement therapy) than subjects who don't have ...
The best studies for assessing whether a screening test will increase a population's health are rigorous randomized controlled trials.When studying a screening program using case-control or, more usually, cohort studies, various factors can cause the screening test to appear more successful than it really is. A number of different biases ...
Case series have a descriptive study design; unlike studies that employ an analytic design (e.g. cohort studies, case-control studies or randomized controlled trials), case series do not, in themselves, involve hypothesis testing to look for evidence of cause and effect (though case-only analyses are sometimes performed in genetic epidemiology ...
This analysis can be restricted to only the participants who fulfill the protocol in terms of the eligibility, adherence to the intervention, and outcome assessment. This analysis is known as an "on-treatment" or "per protocol" analysis. A per-protocol analysis represents a "best-case scenario" to reveal the effect of the drug being studied.
In late July, Super Micro's auditor at the time, Ernst & Young (EY), raised concerns about the company's governance, transparency and internal control over financial reporting, prompting its board ...
In 2014, Jacob Stegenga defined a hierarchy of evidence as "rank-ordering of kinds of methods according to the potential for that method to suffer from systematic bias". At the top of the hierarchy is a method with the most freedom from systemic bias or best internal validity relative to the tested medical intervention's hypothesized efficacy.